Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not ...
Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now ...
The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...
Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...
Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today ...
The FDA’s abrupt shift on UniQure’s treatment reflects an agency that, under current leadership, is as unpredictable as its been in years, some analysts said.
Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.
The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...
11don MSN
International experts produce guidelines for treating hereditary hearing loss with gene therapy
Up to 60% of congenital and early-onset hearing loss is caused by genetic mutations in an inherited gene, and gene therapy ...
Will Lewis, Insmed CEO, joins 'Fast Money' to talk Insmed's rare gene therapy development, demand, and quarterly results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback